American Association of Cancer Research (AACR) Annual Meeting, Chicago, Apr 14-18, 2018 – Poster presentation:
The “classical” co-inhibitory PD-1/PD-L1 pathway is not very common in SCLC, but IHC-analysis of the expression and significance of PVR (CD155)-TIGIT/CD226 axis in SCLC highlights a potential role for checkpoint blockade of the TIGIT pathway and may represent a potent therapeutic strategy in SCLC therapy.
Data provided by:
Hirsch Biomarker Analysis Laboratory, Divison of Medical Oncology, Anschutz Medical Campus, University of Colorado Denver, Aurora, CO, USA.
Radiation Oncology Center NU-Med, Elblag, Poland.
Department of Tumor Biology, National Kuranyi Institute of Pulmonology, Budapest, Hungary.